ARDELYX, INC. (ARDX) Profit Breakdown
- 2026-06-30: Reportable -$12.43M.
- 2025-06-30: Reportable -$14.39M.
Complete filed revenue-to-profit bridge showing gross profit, operating income, pre-tax income and net income.
- Available history
- 2012-12-31 to 2026-06-30
- Data captured
Profit by product
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | -$12.43M |
| 2025-06-30 | -$14.39M |
Net Income (Loss) Attributable to Parent: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | -$16.72M |
| 2025-06-30 | -$19.08M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |